Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in ...

Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid ...

“IN8bio stands at the forefront of gamma-delta T cell innovation, pioneering transformative therapies for cancer patients with urgent unmet needs. Driven by our commitment to scientific ...

"IN8bio stands at the forefront of gamma-delta T cell innovation, pioneering transformative therapies for cancer patients with urgent unmet needs. Driven by our commitment to scientific excellence, we ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

GammaDelta’s drug platform is based on the unique properties of gamma delta (γδ) T cells, a class of lymphocytes that play a role to many types of immune responses and immunopathology.

The Abingworth-backed biotech is developing therapies based on the unique properties of gamma delta (γδ) T cells, a class of lymphocytes that play a role in a host of immune responses and ...

Pulse Biosciences, Inc. , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablationtm (nanosecond PFA or nsPFAtm) technology, today announced plans to present at the upcoming ...

A novel AI-driven method helps scientists stay ahead of viral evolution by engineering synthetic spike proteins that ...

Story March 18 - TC BioPharm: The Scottish biotech developing allogeneic gamma-delta T cell therapies is outsourcing several functions, resulting in a workforce reduction of 20 employees.